Podcast appearances and mentions of Gregory Zuckerman

El problema de los inversores de este país es que solo conocen dos posiciones. O contratan un depósito excesivamente conservador que apenas cubre la inflación, o se lo juegan todo a la shitcoin más loca que encuentran. Pablo Gil, gran conocedor de los mercados, plantea un punto intermedio: fíjate expectativas realistas que se ajusten a tu perfil de riesgo, construye una cartera diversificada y opera con la cabeza fría. Los mercados pueden parecer peligrosos, pero no lo son si entiendes lo que estás haciendo.Pablo Gil ofrece una formación que presenta algunas similitudes con El Proyecto K. Comparto link para que puedas echar un vistazo a su propuesta. En esta industria plagada de charlatanes, es bueno que haya contenido como el suyo, producido por un profesional con experiencia contrastada. Los buenos formadores generan una externalidad positiva, no solo permiten que la gente invierta mejor su dinero, sino que también dan credibilidad a un sector necesitado de perfiles competentes y honestos.Kapital es posible gracias a sus colaboradores:⁠⁠Smartick⁠⁠. El método online de matemáticas y lectura.¿Quieres el mejor futuro para tus hijos? En deporte, España es una potencia mundial, pero en matemáticas y comprensión lectora sigue sin remontar en PISA. Tú puedes cambiar eso para tus hijos. Si tienen entre 4 y 14 años, con Smartick conseguirán dominar los pilares de su educación: matemáticas, comprensión lectora, escribir bien y con claridad, pensamiento crítico. Solo 15 minutos y listos, con un método online personalizado y basado en evidencias científicas. Detrás hay más de 100 expertos en didáctica, empeñados en que tus hijos alcancen su máximo potencial. Cada día recibirás un informe con su evolución y la posibilidad de consultar en todo momento con el equipo. Smartick fomenta la constancia, el gusto por el reto, los buenos hábitos… y también un uso responsable de la tecnología.Prueba 7 días gratis y, si contratas, consigue un precio especial añadiendo el código KAPITAL.⁠Balance Phone⁠. El móvil sin distracciones.Balance Phone nace como una rebelión contra la dependencia digital. Un teléfono sin redes, sin juegos, sin algoritmos que compiten por tu atención. Solo lo esencial. Diseñado para familias que quieren dar un primer móvil sin riesgos a sus hijos y para minimalistas digitales que quieren recuperar el control. No es un Nokia. Es un Samsung con sistema operativo propio, el Balance OS, que bloquea de raíz todo contenido adictivo (redes, pornografía, juegos, apuestas y streaming) y simplifica la interfaz para que usarlo sea una decisión, no un reflejo. 9 meses después de su lanzamiento más de 3.000 persones ya usan Balance Phone. Y lo más importante, con un tiempo de uso diario de 1 hora y 41 minutos, 3 horas por debajo de la media.En Balance Phone no quieren que vivas sin móvil. Quieren que vivas mejor con él.Utiliza el código KAPITAL en su fantástica web para obtener un descuento de 20€.Patrocina Kapital. Toda la información en este link.Índice:0:25 El nefasto concepto de jugar en bolsa.7:42 No hay atajos en el patrimonio.12:28 Amenazante crisis de deuda.20:01 Las trampas del PIB.27:57 Nietzsche frente al borreguismo.35:08 El tuit de Pablo sobre la desinformación.43:46 No hay privacidad sin efectivo.53:01 La vida antes de internet.1:03:07 Quien saca alfa no vende cursos.1:14:15 Nunca mires el precio de tus acciones.1:21:11 Una libreta con el IPC real.1:26:29 Falsas dietas QE.Apuntes:Aprendiendo de las crisis anteriores para invertir con éxito en el futuro. Pablo Gil.El cisne negro. Nassim Nicolas Taleb.1984. George Orwell.Why AI will widen the gap between superstars and everybody else. Matthew Call.El hombre que descifró el mercado. Gregory Zuckerman.

Short Description What Billionaire Traders Don't Want You To Know, Gregory Zuckerman Interview takes you behind the curtain with one of journalism's most revered finance reporters, Gregory Zuckerman. In this episode, Zuckerman shares the psychology and secrets of billionaire traders, from why unchecked power and “yes‑men” can lead to failure, to how he manages the tension between breaking billion‑dollar stories and maintaining integrity. He also reveals an intriguing perspective on the role of AI in journalism: how, even when only 30 percent of AI's suggestions are useful, those contributions can sharpen clarity and strengthen storytelling.Listen as Zuckerman recounts his decade‑spanning investigative career: uncovering Wall Street scandals like the London Whale, chronicling John Paulson's record‑breaking subprime trade (The Greatest Trade Ever), exploring the rise of quantitative investing (“The Man Who Solved the Market”), and tracing the high‑stakes race for a COVID‑19 vaccine (A Shot to Save the World). In an industry where timing matters but accuracy is paramount, he explains why thoughtful skepticism and human connection remain essential.This episode is essential for traders and market observers who want to understand not just the how of investing strategies, but the who, and what they fear.What You'll Learn in This Episode In this interview, you'll discover the hidden forces that shape elite investing and financial journalism. Gregory Zuckerman demystifies the often unseen vulnerabilities of billionaire traders— how isolation and surrounded by agreement, even the most successful investors become prone to mistakes. He offers a rare window into how high-stakes stories are researched and verified, emphasizing that accuracy must always trump urgency.You'll explore the surprising but growing role of AI in journalism. Zuckerman shares how AI tools—though imperfect—enhance the writing process by highlighting weak phrasing, redundant passages, and clarity issues. Learn why combining human judgment with machine insights—“man + machine”—remains the most powerful tool in storytelling and reporting.Drawing on scoops from John Paulson's subprime trade to Jim Simons's quant revolution and the COVID‑19 vaccine saga, he demonstrates how curiosity, persistence, and access to sources underpin the most impactful stories. Whether you're a retail trader seeking competitive edges or an aspiring journalist, this episode delivers actionable insights into strategy, ethics, and the evolving dynamics between humans and technology in finance.Jonathan Farrelly – HostJonathan began his trading journey over 15 years ago, learning from top institutional traders. Over the last nine years, he has educated thousands of retail traders on how to navigate markets effectively. Jonathan's ethos centers on transparency, with the goal of helping both new and experienced traders succeed.About Gregory ZuckermanGregory S. Zuckerman is a Special Writer at The Wall Street Journal with more than 25 years of experience covering finance, energy, biotechnology, and investing. A three-time Gerald Loeb Award winner, he is the author of acclaimed books including The Greatest Trade Ever, The Frackers, The Man Who Solved the Market, A Shot to Save the World, and two inspiring titles for young readers co-authored with his sons, Rising Above and Rising Above: Inspiring Women in Sports

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  1/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  2/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  3/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  4/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  5/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition 1918 SEATTLE https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  6/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition1918 ST. LOUIS https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  7/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

EVERY DETAIL ABOUT THE PANDEMIC NOW IN QUESTION:  8/8  A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

This is The Briefing, a daily analysis of news and events from a Christian worldview.Part I (00:13 – 13:52)Will a Socialist Muslim Become Mayor of New York? Zohran Mamdani Wins the Democratic Party's Primary Race in New YorkWall Street Panics Over Prospect of a Socialist Running New York City by The Wall Street Journal (Kevin T. Dugan, Gregory Zuckerman, and Brian Schwartz)The People's Republic of New York City by The Wall Street Journal (The Editorial Board)Part II (13:52 – 21:00)The 10-Year Anniversary of Obergefell: Obergefell was a Terrible Constitutional Ruling, and Its Ripple Effects Have Been MassiveRoll Back Legal Same-Sex Marriage? Republicans Are Getting It Wrong. by The New York Times (Kristen Soltis Anderson)Resolution: On Restoring Moral Clarity through God's Designfor Gender, Marriage, and the Family by The Southern Baptist Convention Part III (21:00 – 24:27)We are Now 3 Years Post-Dobbs: Returning Abortion to the States was a Necessary Step in the Fight for Life— But Defenders of Life Must Press OnwardSign up to receive The Briefing in your inbox every weekday morning.Follow Dr. Mohler:X | Instagram | Facebook | YouTubeFor more information on The Southern Baptist Theological Seminary, go to sbts.edu.For more information on Boyce College, just go to BoyceCollege.com.To write Dr. Mohler or submit a question for The Mailbox, go here.

Award-winning Wall Street Journal writer Gregory Zuckerman joins host Howard Schweitzer to explore how today's political landscape is shaping global markets. Drawing on nearly 30 years of reporting, Zuckerman offers sharp insights into the intersection of markets, politics, policy, and culture. Featuring Public Strategies' CEO Howard Schweitzer and WSJ's Gregory Zuckerman.

Founders ✓ Claim : Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- Jim Simons never took a single class on finance, wasn't interested in business, and didn't start trading full time until he was 40. The company he founded —  Renaissance Technologies — has made over $100 billion in profits.Starting out with the heretical belief that there was a hidden structure in financial markets, Jim decided to staff his “crazy hedge fund” with mathematicians, computer scientists, and physicists. He went to great lengths to collect more historic financial data than anyone else, spent a lot of time recruiting “killers” (people with single minded focus that wouldn't quit), invested heavily in computers (and the people who ran them), and designed the most collaborative work environment.Jim was a world-class mathematician, code breaker, exceptional manager of people with exceptional minds, a genius in system design, and deeply understood the power of incentives. He was also incapable of giving up, willing to endure a decade of struggle and pain, and hell-bent on doing something “historic” with his life.Jim Simons lived a life defined by persistence, unconventional thinking, and an unwavering pursuit of excellence. Studying his life and work is time well spent. This episode is what I learned from rereading The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution by Gregory Zuckerman. ----Ramp gives you everything you need to control spend, watch your costs, and optimize your financial operations —all on a single platform. Make history's greatest entrepreneurs proud by going to Ramp and learning how they can help your business control your costs and save more. ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work.  Get access to Founders Notes here. ----Join my free email newsletter to get my top 10 highlights from every book ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work. Get access to Founders Notes here. ----“I have listened to every episode released and look forward to every episode that comes out. The only criticism I would have is that after each podcast I usually want to buy the book because I am interested so my poor wallet suffers. ” — GarethBe like Gareth. Buy a book: All the books featured on Founders Podcast

Jim Simons never took a single class on finance, wasn't interested in business, and didn't start trading full time until he was 40. The company he founded —  Renaissance Technologies — has made over $100 billion in profits.Starting out with the heretical belief that there was a hidden structure in financial markets, Jim decided to staff his “crazy hedge fund” with mathematicians, computer scientists, and physicists. He went to great lengths to collect more historic financial data than anyone else, spent a lot of time recruiting “killers” (people with single minded focus that wouldn't quit), invested heavily in computers (and the people who ran them), and designed the most collaborative work environment.Jim was a world-class mathematician, code breaker, exceptional manager of people with exceptional minds, a genius in system design, and deeply understood the power of incentives. He was also incapable of giving up, willing to endure a decade of struggle and pain, and hell-bent on doing something “historic” with his life.Jim Simons lived a life defined by persistence, unconventional thinking, and an unwavering pursuit of excellence. Studying his life and work is time well spent. This episode is what I learned from rereading The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution by Gregory Zuckerman. ----Ramp gives you everything you need to control spend, watch your costs, and optimize your financial operations —all on a single platform. Make history's greatest entrepreneurs proud by going to Ramp and learning how they can help your business control your costs and save more. ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work.  Get access to Founders Notes here. ----Join my free email newsletter to get my top 10 highlights from every book ----Founders Notes gives you the ability to tap into the collective knowledge of history's greatest entrepreneurs on demand. Use it to supplement the decisions you make in your work. Get access to Founders Notes here. ----“I have listened to every episode released and look forward to every episode that comes out. The only criticism I would have is that after each podcast I usually want to buy the book because I am interested so my poor wallet suffers. ” — GarethBe like Gareth. Buy a book: All the books featured on Founders Podcast

Last week, U.S. stocks lost $6.6 trillion in value during a two-day washout after President Trump announced large tariffs on countries around the world. As markets continue to swing, Wall Street leaders are speaking out, including billionaire investor Bill Ackman and JPMorgan Chase executive Jamie Dimon. Host Kate Linebaugh talks with Gregory Zuckerman about the market chaos and how investors are responding.  Further Listening: -Trump's Tariffs Force a New Era in Global Trade  -Trump 2.0: Trade Wars and Deportation Battles  Sign up for WSJ's free What's News newsletter . Learn more about your ad choices. Visit megaphone.fm/adchoices

P.M. Edition for Mar. 17. Condo sales are falling through when would-be buyers find that the property they want to purchase is on a mostly secret mortgage blacklist maintained by Fannie Mae. WSJ insurance reporter Jean Eaglesham tells us about the list and why it is growing. Plus, President Trump lays the groundwork for investigating people pardoned by President Joe Biden. And recent market volatility is leaving even hedge funds floundering. We hear from WSJ special writer Gregory Zuckerman about the funds' impact on the broader market and what signals they will be looking at in the near future. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Youtube - https://youtu.be/uPU6hJsvMcMCurious Worldview Newsletter - https://curiousworldview.beehiiv.com/subscribeGregory Zuckerman is one of the Wall Street Journal GOATS and as well has authored plenty of wonderful books. He pulls back many of the hidden curtains of wall st. The big egos, the big enigmatic personalities, and naturally as well, the big brilliance behind these masters of the universe types. None for emblematic than Jim Simon's, the central character of todays podcast.Theres a podcast called, Acquired, which did a fantastic episode of RenTech (if you want more), the boys over there also relied heavily on Greg's work to put the episode together. 00:00 - Gregory Zuckerman01:27 - Secrecy All The Way Down06:27 - Acquired08:02 - Obscure Datasets15:07 - It Will Take Longer Than You Think20:04 - Jim's Eye For Talent22:27 - Discoveries From Within RenTech28:54 - Greg's Admiration For Jim & 50+ Year Olds Making It35:27 - Nassim Taleb39:01 - Consequences Of Size41:47 - Acquired Podcast & Bob Mercer44:07 - Politics Infecting Interpersonal Dynamics46:07 - Super Quants Can't Recreate RenTech50:47 - Journalism As Sales53:17 - How Does One Conduct A Good Interview?57:37 - The Most Important Question About RenTech Noone Asks59:13 - Decline Of Journalism1:11:14 - The Role Of Serendipity In Greg's Life

Chris Rongey and Amy Marxkors explore the rapid advancements in the AI sector, focusing on the rise of DeepSeek, a Chinese AI company claiming to have developed a superior model at a fraction of the cost compared to industry leaders like OpenAI. Wall Street Journal's Gregory Zuckerman shares insights into DeepSeek's founder, Liang Wenfeng, and his background in quantitative investing. They discuss the impact of DeepSeek on tech stocks, AI market dynamics, and the geopolitical ramifications, including its role in a new potential "Cold War."

THE HASTE WAS THE KNOWN RISK: 6/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 NSW AUSTRALIA

THE HASTE WAS THE KNOWN RISK: 1/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 CAMP FUNSTON, KANSAS

THE HASTE WAS THE KNOWN RISK: 2/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 COLORADO

THE HASTE WAS THE KNOWN RISK: 3/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 SEATTLE

THE HASTE WAS THE KNOWN RISK: 4/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1918 ST. LOUIS

THE HASTE WAS THE KNOWN RISK: 5/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 QUEENSLAND AUSTRALIA QUARENTINE CAMP

THE HASTE WAS THE KNOWN RISK: 7/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 TOKYO

PREVIEW: Conversation with author Gregory Zuckerman in 2021 for his "A Shot to Save the World," re the race for a COVID vaccine, and how the years of blind alleys for some, and frustration with the monetizing of vaccines, as compared to drugs, delivered the breakthrough. More later. 1918 DC

PREVIEW: Conversation with author Gregory Zuckerman in 2021 for his "A Shot to Save the World," re the haste that skipped adequate sized and demographic trials for the vaccines -- leading to lots of doubts about side effects. More later. 1918 DC

THE HASTE WAS THE KNOWN RISK: 8/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition https://www.amazon.com/Shot-Save-World-Life-Death/dp/059342039X/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed. 1919 CAMP FUNSTON

In this episode, Gregory Zuckerman joins us to discuss his book, The Man Who Solved the Market, which chronicles the remarkable journey of Jim Simons. Simons, a mathematician turned investor, co-founded Renaissance Technologies and achieved an astonishing 66% annual return before fees with his Medallion Fund. Zuckerman sheds light on Simons' systematic trading approach, blending advanced algorithms with human intuition. He also addresses the role of AI in modern finance, emphasizing that while technology is crucial, human insight remains essential. Additionally, Zuckerman talks about his other works which aim to inspire young people through stories of overcoming adversity. Tune in to gain insights into the intersection of human and machine in finance and the power of inspirational storytelling.

P.M. Edition for Aug. 12. The rapid decline of several popular trades and the heavy use of leverage sparked last week's markets meltdown. WSJ special writer Gregory Zuckerman breaks down how borrowed money and risky bets set off a stock-market roller coaster. And Heard on the Street columnist Jinjoo Lee explains why the AI boom could cause a hike in Americans' power bills. Plus, Israel puts its military on high-alert on the possibility of an attack by Iran and Hezbollah. Francesca Fontana hosts.  Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Gregory Zukerman writes for the Wall Street Journal. Over the last few decades he has written several books. In 2019 he wrote "The Man Who solved the market: How Jim Simons Launched The Quant Revolution" which became a runaway hit. It tells the story of a genius mathematician who used modern quantitative techniques to make money for himself and his investors. Since 1988 one of the fund's operated by Mr Simons generated average annual returns of 66%. Legendary investors like Warren Buffet, George Soros and Peter Lynch, too, cannot claim to have made these outsized profits with such consistency. How did Mr Simons go about his business? How did he manage a stellar team while keeping them movitated? How did he use machine learning, artificial intelligence, data and analytics in an era when these terms were unheard of in the industry? Gregory Zukerman explains it all in this podcast.

P.M. Edition for May 17. The Dow officially closed above 40000 today, for the first time ever. Special writer Gregory Zuckerman explains why investors are striking gold—and how long it could last. And Heard on the Street columnist David Wainer has more on why the Medicare bubble may have burst. Plus, workers at a Mercedes-Benz plant in Alabama reject unionization, in a setback for the United Auto Workers union. Annmarie Fertoli hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jim Simons pioneered a revolution in financial trading, embracing a computer-oriented, quantitative style in the 1980s well ahead of Wall Street. Following Simons' recent death, WSJ's Gregory Zuckerman unpacks his legacy from financial algorithms to philanthropy.  Further Reading: -How Did Jim Simons's Firm Make $100 Billion? He Told His Secrets to Our Reporter  -Jim Simons, a Pioneer of Quantitative Trading, Dies at 86  -The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution  Further Listening: -Charlie Munger: Curmudgeon, Sage and Investing Legend  -Rise and Revolt at Renaissance, Part 1  -Rise and Revolt at Renaissance, Part 2  Learn more about your ad choices. Visit megaphone.fm/adchoices

Gregory Zukerman writes for the Wall Street Journal. Over the last few decades he has written several books. In 2019 he wrote "The Man Who solved the market: How Jim Simons Launched The Quant Revolution" which became a runaway hit. It tells the story of a genius mathematician who used modern quantitative techniques to make money for himself and his investors. Since 1988 one of the fund's operated by Mr Simons generated average annual returns of 66%. Legendary investors like Warren Buffet, George Soros and Peter Lynch, too, cannot claim to have made these outsized profits with such consistency. How did Mr Simons go about his business? How did he manage a stellar team while keeping them movitated? How did he use machine learning, artificial intelligence, data and analytics in an era when these terms were unheard of in the industry? Gregory Zukerman explains it all in this podcast.

A conversation with Gregory Zuckerman, an award-winning writer for The Wall Street Journal and author of "The Man Who Solved Wall Street". We dive deep into the world of quant investing, exploring the journey of renowned mathematician, investor, and Founder of Renaissance Technologies, Jim Simons, together with his extraordinary team.  Watch it on YouTube https://youtu.be/_5JkBUeLOLQ REFERENCES ▶️The book: https://www.waterstones.com/book/the-man-who-solved-the-market/gregory-zuckerman/9780241309735 ▶️Greg's website: https://www.gregoryzuckerman.com/ ▶️ Follow Greg on Twitter: https://twitter.com/gzuckerman? TO GO FURTHER

Efficiency experts say you must plan your work and work your plan. And you must have written goals and a budget and a schedule.A detailed plan is the key to success when you are doing something small, but you cannot have a detailed plan when you are doing something big and new and untried.You know a project is small when all the variables can be known in advance.When you do something big and new and untried, you will come to a place that your plan did not foresee. This is when you must improvise. Later, you will discover that you are making decisions at the last moment, because that is when you have the most information.Possibilities are in your mind. Reality is at your fingertips. So get started. Move. Take action. Do something.Clarity, commitment, and continual improvement are what you need most when doing something big and new and untried.1: Clarity means you have a clear vision of the outcome you are hoping to bring into reality.2: When you have clarity, you always know what to do next.3: Commitment means that quitting will never occur to you.4: When you have commitment, you find a solution to every obstacle.5: Continual Improvement means that you touch your project every day without fail.6: Touching your project every day – and moving it forward a little – unleashes the power of Exponential Little Bits, the energy that spins your flywheel.7: A thousand tiny touches don't add up, they multiply. Two becomes four. Four becomes eight. Eight becomes sixteen, and 28 cycles later you have exceeded one billion.8: The only things you cannot know in advance are(A.) How long is it going to take?(B.) How much is it going to cost?9: If you insist on knowing those answers in advance, these are the answers:(A.) It will take as long as it takes(B.) It will cost what it costs.10: If you demand answers with more details, you either lack commitment or you believe I can see the future.11: I cannot see the future.12: The only hard part is step number one.You will notice I have given you a 12-step program. This is because doing things that are big, new, and untried is highly addictive, and every addictive thing has its own 12-step program.Do not confuse it with a plan.Roy H. WilliamsPS – George Bernard Shaw said, “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” Roy might tell you more about George Bernard Shaw next week. Or then again, maybe not. – IndyCharlie Munger was the billionaire businessman who built Berkshire Hathaway side-by-side with Warren Buffett. Just weeks before Munger died at age 99, Gregory Zuckerman of The Wall Street Journal spent 4 hours with Charlie in the billionaire's Los Angeles home and came away with some life-changing insights. This week, roving reporter Rotbart interviews the last journalist to interview Charlie Munger, which makes everyone who listens to this week's episode of Monday Morning Radio just three degrees of separation from Charlie Munger and four degrees from Warren Buffett. How can you resist? This party will start the moment you arrive at MondayMorningRadio.com.

Can you imagine what it would have been like to have an exclusive four-hour audience with the late Charlie Munger?  The billionaire businessman, who died in late November at age 99, never got as much press as his close friend and partner Warren Buffett. But many people credited Munger with helping secure Berkshire Hathaway's decades-long stellar investment performance. Just weeks before Munger passed, The Wall Street Journal veteran reporter Gregory Zuckerman visited Munger in the investor's Los Angeles home and came away with some unique and actionable insights.  This week, award-winning author and Monday Morning Radio founder Dean Rotbart interviews the last journalist to interview Munger. That makes everyone who listens to this week's episode only three degrees of separation from Munger and four degrees from Buffett. It's always nice to know people who know people. And, importantly, to learn what they know. Monday Morning Radio is hosted by the father-son team of Dean and Maxwell Rotbart. Photo: Greg Zuckerman, The Wall Street JournalPosted: January 8, 2024Monday Morning Run Time: 37:06Episode: 12.27 To show your appreciation for Monday Morning Radio and keep it commercial-free, we encourage you to contribute using this link. Donations of all sizes are welcome.

On today's episode, we revisit a conversation we had with two pioneers of the mRNA-based Covid-19 vaccines, Katalin Karikó, PhD, and Drew Weissman, MD, PhD. The two were just awarded the 2023 Nobel Prize in Physiology or Medicine for their groundbreaking research in messenger RNA (mRNA) technology. When we spoke with Dr. Kariko and Weissman in June 2022, they had just received the Ross Prize in Molecular Medicine. The Feinstein Institutes for Medical Research grants this honor to recognize promising careers in the fields of science and research. In this look back on that conversation, the history-making duo discusses what motivated them to endure their decades-long scientific struggles, plans to continue their mRNA research and what it means to be awarded the Ross Prize. Also on the show, we speak with Kevin Tracey, MD, president of the Feinstein Institutes for Medical Research, about the importance of supporting young scientists, early-stage research and the culture of science. Meet the experts Katalin Kariko, PhD, adjunct professor of Neurosurgery at the University of Pennsylvania and a senior vice president at BioNTech Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research in Penn's Perelman School of Medicine The award Drs. Kariko and Weissman received is one of six categories that are recognized each year. Since 1901, there have been 114 prizes in the Physiology or Medicine category awarded to 227 laureates.  Learn more about the Nobel Prize  Learn more about Drs. Kariko and Weissman.  More on the history of mRNA technology Learn more about the history of mRNA technology and the development of the Covid-19 vaccines on this episode of the podcast, featuring Wall Street Journal writer, Gregory Zuckerman, and two of the first Americans to receive the vaccine, Sandra Lindsay and Yves Duroseau, MD.  Watch episodes of 20-Minute Health Talk on YouTube. 

George Soros, the legendary investor, philanthropist and right-wing target, is handing control of his $25 billion empire to his fourth child—Alexander Soros, a former party boy and self-described center-left thinker. WSJ's Gregory Zuckerman on how Alex Soros plans to deploy his family's vast fortune. Further Reading: - George Soros Hands Control to His 37-Year-Old Son  - The Soros Era Is Over on Wall Street  Interested in other succession stories? Listen to: - The World's Richest Person Is Planning for Succession  - Scholastic's Succession Drama  Learn more about your ad choices. Visit megaphone.fm/adchoices

Early staffers at Sam Bankman-Fried's first company, Alameda Research, say they quit over his approach to risk, compliance and accounting. How similar were those issues to ones that arose at the crypto exchange FTX? Wall Street Journal special writer Gregory Zuckerman joins host Zoe Thomas to discuss what happened at Alameda and how much it foreshadowed FTX's downfall. Learn more about your ad choices. Visit megaphone.fm/adchoices

Photo: No known restrictions on publication. @Batchelorshow MrMarket: FTX blows up in predictable tomfoolery. Gregory Zuckerman, WSJ. https://www.wsj.com/articles/ftx-hires-ex-regulators-to-investigate-firms-collapse-11669233784

Photo: #Markets: Black Swans every Perfect Storm. Gregory Zuckerman, WSJ. https://www.wsj.com/articles/black-swans-and-perfect-storms-wall-street-reaches-for-cliche-to-excuse-your-withered-401-k-11657206520?mod=Searchresults_pos1&page=1

Photo: No known restrictions on publication. @Batchelorshow 4/8:  Still a miracle.By  Gregory Zuckerman. 4/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 6/8:  Still a miracle.By  Gregory Zuckerman. 6/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 5/8:  Still a miracle.By  Gregory Zuckerman. 5/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 7/8:  Still a miracle.By  Gregory Zuckerman. 7/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 3/8: Still a miracle.By  Gregory Zuckerman. 3/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 2/8:  Still a miracle.By  Gregory Zuckerman. 2/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 1/8:  Still a miracle.By  Gregory Zuckerman. 1/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.

Photo: No known restrictions on publication. @Batchelorshow 8/8:  Still a miracle.By  Gregory Zuckerman. 8/8   A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, by  Gregory Zuckerman   Kindle Edition Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches. Their work was met with skepticism and scorn. By 2020, these individuals had little proof of progress. Yet they and their colleagues wanted to be the ones to stop the virus holding the world hostage. They scrambled to turn their life's work into life-saving vaccines in a matter of months, each gunning to make the big breakthrough—and to beat each other for the glory that a vaccine guaranteed.